Display options
Cite
Mori H, Suzuki H, Matsuzaki J, et al. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study. United European Gastroenterol J. 2015;4(3):380-7doi: 10.1177/2050640615618043.
Mori, H., Suzuki, H., Matsuzaki, J., Tsugawa, H., Fukuhara, S., Miyoshi, S., Hirata, K., Seino, T., Matsushita, M., Nishizawa, T., Masaoka, T., & Kanai, T. (2016). Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study. United European gastroenterology journal, 4(3), 380-7. https://doi.org/10.1177/2050640615618043
Mori, Hideki, et al. "Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study." United European gastroenterology journal vol. 4,3 (2016): 380-7. doi: https://doi.org/10.1177/2050640615618043
Mori H, Suzuki H, Matsuzaki J, Tsugawa H, Fukuhara S, Miyoshi S, Hirata K, Seino T, Matsushita M, Nishizawa T, Masaoka T, Kanai T. Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study. United European Gastroenterol J. 2016 Jun;4(3):380-7. doi: 10.1177/2050640615618043. Epub 2015 Nov 13. PMID: 27403304; PMCID: PMC4924440.
Copy Download .nbib Format: NLM
Share it on

United European Gastroenterol J. 2016 Jun;4(3):380-7. doi: 10.1177/2050640615618043. Epub 2015 Nov 13.

Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.

United European gastroenterology journal

Hideki Mori, Hidekazu Suzuki, Juntaro Matsuzaki, Hitoshi Tsugawa, Seiichiro Fukuhara, Sawako Miyoshi, Kenro Hirata, Takashi Seino, Misako Matsushita, Toshihiro Nishizawa, Tatsuhiro Masaoka, Takanori Kanai

Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  2. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; Medical Education Center, Keio University School of Medicine, Tokyo, Japan.
  3. Department of Biochemistry and Integrative Medical Biology, Keio University School of Medicine, Tokyo, Japan.

PMID: 27403304 PMCID: PMC4924440 DOI: 10.1177/2050640615618043

Abstract

BACKGROUND AND AIM: This prospective randomized study was designed to assess the efficacy of 10-day and 14-day rifabutin-based triple therapy as a third- or fourth-line rescue therapy.

METHODS: Patients who failed first- and second-line eradication therapy were enrolled. H. pylori was isolated from gastric biopsy specimens and the rpoB mutation status, a factor of resistance to rifamycins, and minimum inhibitory concentrations (MICs) of rifabutin and amoxicillin were determined. Enrolled patients were randomly assigned to receive 10-day or 14-day eradication therapy with esomeprazole (20 mg, 4 times a day (q.i.d.)), amoxicillin (500 mg, q.i.d.), and rifabutin (300 mg, once a day (q.d.s.)). Poor compliance was defined as intake of <80% of study drugs. Successful H. pylori eradication was confirmed using a [13C] urea breath test or a stool antigen test, 12 weeks after the end of therapy.

RESULTS: Twelve patients were assigned to the 10-day group, and 17, to the 14-day group. Intention-to-treat and per-protocol analyses of eradication rates were 83.3% and 81.8% for the 10-day group and 94.1% and 91.7% for the 14-day group, respectively. All patients with rpoB mutation-positive strains (n = 3) showed successful eradication, irrespective of the regimen received. Therapy was stopped due to adverse events in 8.3% and 29.3% of patients in the 10-day and 14-day groups, respectively.

CONCLUSION: Both the 10-day and 14-day therapies were effective as rescue regimens. In particular, the 14-day therapy resulted in successful eradication in over 90% of patients, but the 10-day treatment may be enough to obtain a successful eradication rate, considering the tolerability of therapy.

Keywords: Rifabutin; amoxicillin; rpoB

References

  1. Digestion. 2009;79(1):1-4 - PubMed
  2. Helicobacter. 2014 Aug;19(4):319-22 - PubMed
  3. J Gastroenterol. 1998;33 Suppl 10:36-9 - PubMed
  4. Antimicrob Agents Chemother. 1999 Jun;43(6):1497-9 - PubMed
  5. Aliment Pharmacol Ther. 2012 Jan;35(2):209-21 - PubMed
  6. Aliment Pharmacol Ther. 2012 May;35(9):1097-102 - PubMed
  7. Helicobacter. 2001 Sep;6(3):254-61 - PubMed
  8. Aliment Pharmacol Ther. 2008 Feb 15;27(4):346-54 - PubMed
  9. Lancet. 1999 Jul 3;354(9172):30-3 - PubMed
  10. Clin Gastroenterol Hepatol. 2013 May;11(5):507-10 - PubMed
  11. Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):437-9 - PubMed
  12. Aliment Pharmacol Ther. 2007 Dec;26(11-12):1537-42 - PubMed
  13. J Antimicrob Chemother. 2007 May;59(5):874-9 - PubMed
  14. Gut. 2012 Apr;61(4):507-13 - PubMed
  15. Aliment Pharmacol Ther. 2006 Feb 15;23(4):481-8 - PubMed
  16. J Gastrointestin Liver Dis. 2010 Dec;19(4):409-14 - PubMed
  17. Aliment Pharmacol Ther. 2003 Jan;17(1):119-23 - PubMed
  18. Helicobacter. 2014 Dec;19(6):455-61 - PubMed
  19. Am J Gastroenterol. 2001 Jan;96(1):58-62 - PubMed
  20. Antimicrob Agents Chemother. 2001 Mar;45(3):727-33 - PubMed
  21. Lancet. 2008 Aug 2;372(9636):392-7 - PubMed
  22. J Clin Biochem Nutr. 2010 Jul;47(1):53-8 - PubMed
  23. Antimicrob Agents Chemother. 2011 Nov;55(11):5374-5 - PubMed
  24. Can J Gastroenterol. 2010 May;24(5):303-6 - PubMed
  25. Helicobacter. 2004 Feb;9(1):9-16 - PubMed
  26. Antimicrob Agents Chemother. 2012 Mar;56(3):1643-5 - PubMed
  27. Helicobacter. 2003 Apr;8(2):90-4 - PubMed
  28. Helicobacter. 2013 Dec;18(6):468-72 - PubMed

Publication Types